Invasive fusariosis after CD19 chimeric antigen receptor T-cell therapy
Though rare, healthcare providers should maintain an index of suspicion for <i>Fusarium</i> infections in recipients of cellular therapies with risk factors.
Authors
- Rita Wilson Dib (ORCID: https://orcid.org/0000-0001-7110-8885)
- Annoir Shayya
- Jeffrey D. McBride (ORCID: https://orcid.org/0000-0002-2167-9054)
- Joseph Sassine (ORCID: https://orcid.org/0000-0001-8730-8929)
- Emily A Siegrist (ORCID: https://orcid.org/0000-0002-4282-4134)
- Jennifer Holter‐Chakrabarty (ORCID: https://orcid.org/0000-0003-1425-7002)
- Maria Alkozah (ORCID: https://orcid.org/0000-0002-7274-5453)
- José Henao-Cordero (ORCID: https://orcid.org/0000-0002-1947-8675)
- Brian T. Scott (ORCID: https://orcid.org/0000-0002-1321-7204)
- Cindy B. McCloskey
- Melanie Speckman
Institutions
- University Medical Center Rizk Hospital (LB)
- OU Health
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- ASM Case Reports
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1128/asmcr.00117-24
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00